BPC-157s Category 2 status is still in effect today, so it cant be lawfully compounded in New York this week
In terms of other health indicators, they claim: Significant improvements in blood pressure and hsCRP were seen from baseline to week 72 with semaglutide 7 2 mg versus placebo Note that they are comparing semaglutide 7.2mg to PLACEBO and finding statistically significant differences, but what is the difference between the existing 2.4mg dose and the 7.2mg dose
16,23,37,38,39 Although there are no conclusive data on the mortality rates, it should be investigated in the future
25 BurkR
Previous studies have documented bacterial selenoproteins involved in redox metabolism, including a glutaredoxin in Clostridium oremlandii [42] and a thioredoxin in Treponema denticola [42]
GLP-1 therapies are at risk of entering that same cycle